



**PATENT**  
Attorney Docket No. **OPHD-08311**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: John Kink, *et al.*  
Serial No.: 10/627,499  
Filed: 07/25/03  
Entitled: **Antibodies to Cytokines in the Prevention  
and Treatment of Inflammatory Bowel  
Disease**

Group No. 1646  
Examiner: Xie

**TERMINAL DISCLAIMER TO OBVIATE DOUBLE  
PATENTING REJECTION**

MS - Non Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)**

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Dated: July 7, 2006

By: \_\_\_\_\_

*Jasmine M. Stansberry*  
Jasmine M. Stansberry

Examiner Xie:

I, Jason R. Bond, represent that I am an attorney of record for this invention. The Assignee, Promega Corporation, 2800 Woods Hollow Road, Madison, Wisconsin 53711, is the owner of one-hundred percent (100%) interest in the instant application. The Assignment from the inventors was recorded in the Patent and Trademark Office at Reel 010240, Frame 0201.

Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154 to 156 and 173 of U.S. Patent 6,663,864, and U.S. Patent 6,395,273, and hereby agrees that any patent so granted on the above-identified instant application shall be enforceable only for and during such period that the legal title to said patent be the same as the legal title to


the above referenced patent, this agreement to run with any patent granted on the above-identified instant application and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to 156 and 173, as presently shortened by any terminal disclaimer, in the event that U.S. Patent 6,663,864, and U.S. Patent 6,395,273, should expire for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned is empowered to act on behalf of the assignee.

Dated: July 7, 2006

  
\_\_\_\_\_  
Jason R. Bond  
Reg. No. 45,439  
  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94150  
(608) 218-6900